Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Used in the manufacture of acetophenetidin.
Antibodies produced by a single clone of cells.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Inflammation of the joints of the SPINE, the intervertebral articulations.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Antibodies obtained from a single clone of cells grown in mice or rats.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Substances that reduce or suppress INFLAMMATION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.

New treatment strategies for malignant gliomas. (1/231)

Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.  (+info)

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. (2/231)

Genetically engineered, neuroattenuated herpes simplex viruses (HSVs) expressing various cytokines can improve survival when used in the treatment of experimental brain tumors. These attenuated viruses have both copies of gamma(1)34.5 deleted. Recently, we demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, as compared with treatment with the parent construct (gamma(1)34. 5(-)) alone or with a virus expressing IL-10. Herein, we report construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model. IL-12 induces a helper T cell subset type 1 response, which may induce more durable antitumor effects. In vitro studies showed that, when infected with M002, both Vero cells and murine Neuro-2a neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for Neuro-2a cells and human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitive A/J strain mice found that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than the median survival of animals treated with R3659, the parent gamma(1)34.5(-) mutant lacking any cytokine gene insert. Immunohistochemical analysis of M002-treated tumors identified a pronounced influx of CD4(+) T cells and macrophages as well as CD8(+) cells when compared with an analysis of R3659-treated tumors. We conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.  (+info)

Where is biological therapy going? (3/231)

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chronic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.  (+info)

Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. (4/231)

There is an increasing scientific and commercial interest in the use of beneficial microorganisms, or "probiotics," for the prevention and treatment of disease. The microorganisms most frequently used as probiotic agents are lactic-acid bacteria such as Lactobacillus rhamnosus GG (LGG), which has been extensively studied in recent literature. Multiple mechanisms of action have been postulated, including lactose digestion, production of antimicrobial agents, competition for space or nutrients, and immunomodulation. We have reviewed recent studies of probiotics for the treatment and control of infectious diseases. Studies of pediatric diarrhea show substantial evidence of clinical benefits from probiotic therapy in patients with viral gastroenteritis, and data on LGG treatment for Clostridium difficile diarrhea appear promising. However, data to support use of probiotics for prevention of traveler's diarrhea are more limited. New research suggests potential applications in vaccine development and prevention of sexually transmitted diseases. Further studies are needed to take full advantage of this traditional medical approach and to apply it to the infectious diseases of the new millennium.  (+info)

Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference. (5/231)

The studies presented at the conference indicate that new therapeutic agents are effective for patients with SLE. Some of the agents (high dose cyclophosphamide) may be given to patients with refractory disease while others (low dose cyclophosphamide, and MMF) may be used as a first-line drug. The current data on biologic agents are still preliminary and their exact role in SLE needs to be determined.  (+info)

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. (6/231)

BACKGROUND: Gemcitabine and vinorelbine are two of the most active third-generation agents for the treatment of advanced nonsmall cell lung carcinoma (NSCLC). The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC. METHODS: A total of 78 patients were treated on the current Phase II trial of front-line or second/third-line therapy with gemcitabine and vinorelbine in NSCLC. Eligible patients manifested either untreated disease (n = 42) or had received at least one but not more than two prior chemotherapy regimens (n = 36). The median age was 57.5 years (range, 33-79) with 57 men (73%) and 21 women (27%). The median performance status was one (range, one to two). The initial eight patients (four untreated and four previously treated) were treated at a previously established maximum tolerated dose of vinorelbine (30 mg/m(2)) and gemcitabine (1000 mg/m(2)) on Days 1, 8, and 15, with significant myelosuppression seen in five out of eight patients requiring dose omission in the first cycle. The next 70 patients received a reduced dose of vinorelbine (25 mg/m(2)) followed by gemcitabine (900 mg/m(2)) on Days 1, 8, and 15. RESULTS: Seventy eight patients were treated. Fifteen (36%) of the 42 evaluable patients who received front-line therapy had objective responses and 14 (33%) had stable disease. In the patients with prior treatment, 6 (17%) of 36 patients had partial response and 18 patients (50%) had stable disease. Median survival time for the previously untreated patient group was 10.1 months, with a one year survival of 43% and a two year survival rate of 32%. For the previously treated patients, the median survival time was 8.5 months, with a one year survival rate of 30%. Toxic effects were notable for significant myelosuppression, with > or =Grade 3 granulocytopenia seen in 55% of the patients on the untreated arm and 67% of the patients on the previously treated arm. Additionally, 9.5% and 13.9% (untreated and previously treated), respectively, of these patients experienced Grades 3 and 4 thrombocytopenia at some point in their treatment. A full dose delivery analysis showed that this myelosuppression resulted in Course 1, Day 15 skipped doses (even at the reduced dose level) in 42% of previously untreated patients and 47% of pretreated patients. Other side effects seen at Grades 3 and 4 in previously untreated and treated patients included anemia (9.5% and 2.8%), asthenia (4.8% and 5.5%), infection (14.3% and 5.6%), pain (9.5% and 19.4%), and pulmonary complications (4.8% and 13.8%). CONCLUSIONS: Gemcitabine/vinorelbine is an active, well-tolerated combination in both front-line and second/third-line therapy for Stage IIIB/IV NSCLC. The response rate, median survival rate, and one year survival rate compare favorably with platinum-based regimens. The toxicity profile of the gemcitabine/vinorelbine combination was quite favorable, with minimal Grade 3 and 4 toxic effects aside from granulocytopenia, which resulted in numerous Day 15 skipped doses but no significant febrile neutropenia or infection. The combination of gemcitabine and vinorelbine could be a useful regimen in standard clinical practice and has the potential for efficient combination with biologic/targeted therapy. Multiple randomized trials of this combination versus platinum combinations are now ongoing [corrected].  (+info)

Yoghurt biotherapy: contraindicated in immunosuppressed patients? (7/231)

A fatal case of Lactobacillus rhamnosus septicaemia after prolonged oral vancomycin for recalcitrant Clostridium difficile infection is reported. The patient was immunosuppressed with cyclophosphamide and steroids for Sjogren's syndrome. The administration of Lactobacillus spp as "biotherapy" may be hazardous in such circumstances.  (+info)

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. (8/231)

Live attenuated measles virus (MV-Edm) has potent oncolytic activity against myeloma xenografts in mice. Therapy of multiple myeloma, a disseminated plasma cell malignancy, would require systemic administration of the virus. Thus, the virus should ideally be targeted to infect only myeloma cells to minimize collateral damage to normal tissues: viral binding to its natural receptors must be ablated and a new specificity domain that targets entry into myeloma cells be added. This study covers 2 critical steps toward generating such a retargeted virus: (1) a new specificity domain against the plasma cell marker CD38 was constructed in the form of a single-chain antibody (scFv) and (2) display of that scFv on the measles viral envelope glycoprotein successfully redirected virus entry through CD38 expressed on target cells devoid of the natural MV receptors. The anti-CD38 scFv was tethered to the C-terminus of the hemagglutinin (H) glycoprotein of MV-Edm through a Factor Xa protease cleavable linker. Immunoblot analysis demonstrated that the scFv was efficiently incorporated into recombinant viral particles. Replication of MV-alpha CD38 was not hindered by the scFv, reaching titers comparable to MV-Edm. Chinese hamster ovary (CHO) cells were resistant to infection by MV-Edm and MV-alpha CD38. In contrast, CHO cells expressing CD38 became susceptible to infection by MV-alpha CD38 but not MV-Edm. Removal of the displayed scFv rendered MV-alpha CD38 noninfectious on CHO-CD38 cells. Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group.  (+info)

Biological therapy, also known as biotherapy or immunotherapy, is a type of medical treatment that uses biological agents (such as substances derived from living organisms or laboratory-made versions of these substances) to identify and modify specific targets in the body to treat diseases, including cancer. These therapies can work by boosting the body's natural defenses to fight illness, interfering with the growth and spread of abnormal cells, or replacing absent or faulty proteins in the body. Examples of biological therapies include monoclonal antibodies, cytokines, and vaccines.

According to the United States Food and Drug Administration (FDA), biological products are "products that are made from or contain a living organism or its derivatives, such as vaccines, blood and blood components, cells, genes, tissues, and proteins." These products can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, and they can come from many sources, including humans, animals, microorganisms, or plants.

Biological products are often used to diagnose, prevent, or treat a wide range of medical conditions, and they can be administered in various ways, such as through injection, inhalation, or topical application. Because biological products are derived from living organisms, their manufacturing processes can be complex and must be tightly controlled to ensure the safety, purity, and potency of the final product.

It's important to note that biological products are not the same as drugs, which are chemically synthesized compounds. While drugs are designed to interact with specific targets in the body, such as enzymes or receptors, biological products can have more complex and varied mechanisms of action, making them potentially more difficult to characterize and regulate.

Antirheumatic agents are a class of drugs used to treat rheumatoid arthritis, other inflammatory types of arthritis, and related conditions. These medications work by reducing inflammation in the body, relieving symptoms such as pain, swelling, and stiffness in the joints. They can also help slow down or prevent joint damage and disability caused by the disease.

There are several types of antirheumatic agents, including:

1. Nonsteroidal anti-inflammatory drugs (NSAIDs): These medications, such as ibuprofen and naproxen, reduce inflammation and relieve pain. They are often used to treat mild to moderate symptoms of arthritis.
2. Corticosteroids: These powerful anti-inflammatory drugs, such as prednisone and cortisone, can quickly reduce inflammation and suppress the immune system. They are usually used for short-term relief of severe symptoms or in combination with other antirheumatic agents.
3. Disease-modifying antirheumatic drugs (DMARDs): These medications, such as methotrexate and hydroxychloroquine, work by slowing down the progression of rheumatoid arthritis and preventing joint damage. They can take several weeks or months to become fully effective.
4. Biologic response modifiers (biologics): These are a newer class of DMARDs that target specific molecules involved in the immune response. They include drugs such as adalimumab, etanercept, and infliximab. Biologics are usually used in combination with other antirheumatic agents for patients who have not responded to traditional DMARD therapy.
5. Janus kinase (JAK) inhibitors: These medications, such as tofacitinib and baricitinib, work by blocking the action of enzymes called JAKs that are involved in the immune response. They are used to treat moderate to severe rheumatoid arthritis and can be used in combination with other antirheumatic agents.

It is important to note that antirheumatic agents can have significant side effects and should only be prescribed by a healthcare provider who is experienced in the management of rheumatoid arthritis. Regular monitoring and follow-up are essential to ensure safe and effective treatment.

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the joints. It is characterized by persistent inflammation, synovial hyperplasia, and subsequent damage to the articular cartilage and bone. The immune system mistakenly attacks the body's own tissues, specifically targeting the synovial membrane lining the joint capsule. This results in swelling, pain, warmth, and stiffness in affected joints, often most severely in the hands and feet.

RA can also have extra-articular manifestations, affecting other organs such as the lungs, heart, skin, eyes, and blood vessels. The exact cause of RA remains unknown, but it is believed to involve a complex interplay between genetic susceptibility and environmental triggers. Early diagnosis and treatment are crucial in managing rheumatoid arthritis to prevent joint damage, disability, and systemic complications.

I'm sorry for any confusion, but "Phenetidine" is not a term commonly used in modern medicine or pharmacology. It's possible that you may have misspelled or misremembered the name of a different chemical compound. There is a chemical compound known as "phenetidine" (C6H5CNOH), but it's not used in a medical context and has limited use in organic synthesis.

If you had a different substance in mind, please provide more context or check the spelling, so I can give you a more accurate and helpful response.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Psoriasis is a chronic skin disorder that is characterized by recurrent episodes of red, scaly patches on the skin. The scales are typically silvery-white and often occur on the elbows, knees, scalp, and lower back, but they can appear anywhere on the body. The exact cause of psoriasis is unknown, but it is believed to be related to an immune system issue that causes skin cells to grow too quickly.

There are several types of psoriasis, including plaque psoriasis (the most common form), guttate psoriasis, inverse psoriasis, pustular psoriasis, and erythrodermic psoriasis. The symptoms and severity of the condition can vary widely from person to person, ranging from mild to severe.

While there is no cure for psoriasis, various treatments are available that can help manage the symptoms and improve quality of life. These may include topical medications, light therapy, and systemic medications such as biologics. Lifestyle measures such as stress reduction, quitting smoking, and avoiding triggers (such as certain foods or alcohol) may also be helpful in managing psoriasis.

Psoriatic arthritis is a form of inflammatory arthritis that occurs in some people with psoriasis, a skin condition characterized by scaly, red, and itchy patches. The Arthritis Foundation defines psoriatic arthritis as "a chronic disease characterized by swelling, pain, and stiffness in and around the joints. It usually affects the fingers and toes but can also affect the lower back, knees, ankles, and spine."

Psoriatic arthritis can cause a variety of symptoms, including:

* Joint pain, swelling, and stiffness
* Swollen fingers or toes (dactylitis)
* Tenderness, pain, and swelling where tendons and ligaments attach to bones (enthesitis)
* Changes in nail growth, such as pitting, ridging, or separation from the nail bed
* Fatigue and weakness
* Reduced range of motion and mobility

The exact cause of psoriatic arthritis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. Treatment typically involves a combination of medications, lifestyle changes, and physical therapy to manage symptoms and prevent joint damage.

Monoclonal antibodies are laboratory-produced proteins that mimic the immune system's ability to fight off harmful antigens such as viruses and cancer cells. They are created by fusing a single B cell (the type of white blood cell responsible for producing antibodies) with a tumor cell, resulting in a hybrid cell called a hybridoma. This hybridoma can then be cloned to produce a large number of identical cells, all producing the same antibody, hence "monoclonal."

Humanized monoclonal antibodies are a type of monoclonal antibody that have been genetically engineered to include human components. This is done to reduce the risk of an adverse immune response in patients receiving the treatment. In this process, the variable region of the mouse monoclonal antibody, which contains the antigen-binding site, is grafted onto a human constant region. The resulting humanized monoclonal antibody retains the ability to bind to the target antigen while minimizing the immunogenicity associated with murine (mouse) antibodies.

In summary, "antibodies, monoclonal, humanized" refers to a type of laboratory-produced protein that mimics the immune system's ability to fight off harmful antigens, but with reduced immunogenicity due to the inclusion of human components in their structure.

Immunologic factors refer to the elements of the immune system that contribute to the body's defense against foreign substances, infectious agents, and cancerous cells. These factors include various types of white blood cells (such as lymphocytes, neutrophils, monocytes, and eosinophils), antibodies, complement proteins, cytokines, and other molecules involved in the immune response.

Immunologic factors can be categorized into two main types: innate immunity and adaptive immunity. Innate immunity is the non-specific defense mechanism that provides immediate protection against pathogens through physical barriers (e.g., skin, mucous membranes), chemical barriers (e.g., stomach acid, enzymes), and inflammatory responses. Adaptive immunity, on the other hand, is a specific defense mechanism that develops over time as the immune system learns to recognize and respond to particular pathogens or antigens.

Abnormalities in immunologic factors can lead to various medical conditions, such as autoimmune disorders, immunodeficiency diseases, and allergies. Therefore, understanding immunologic factors is crucial for diagnosing and treating these conditions.

Dermatologic agents are medications, chemicals, or other substances that are applied to the skin (dermis) for therapeutic or cosmetic purposes. They can be used to treat various skin conditions such as acne, eczema, psoriasis, fungal infections, and wounds. Dermatologic agents include topical corticosteroids, antibiotics, antifungals, retinoids, benzoyl peroxide, salicylic acid, and many others. They can come in various forms such as creams, ointments, gels, lotions, solutions, and patches. It is important to follow the instructions for use carefully to ensure safety and effectiveness.

Spondylarthritis is a term used to describe a group of interrelated inflammatory diseases that primarily affect the spine and sacroiliac joints (where the spine connects to the pelvis), but can also involve other joints, ligaments, tendons, and entheses (sites where tendons or ligaments attach to bones). These conditions share common genetic, clinical, and imaging features.

The most common forms of spondylarthritis include:

1. Ankylosing spondylitis - a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, causing pain and stiffness. In some cases, it can lead to fusion of the spine's vertebrae.
2. Psoriatic arthritis - a form of arthritis that occurs in people with psoriasis, an autoimmune skin condition. It can cause inflammation in the joints, tendons, and entheses.
3. Reactive arthritis - a type of arthritis that develops as a reaction to an infection in another part of the body, often the urinary or gastrointestinal tract.
4. Enteropathic arthritis - a form of arthritis associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.
5. Undifferentiated spondylarthritis - when a patient presents with features of spondylarthritis but does not meet the criteria for any specific subtype.

Common symptoms of spondylarthritis include:

- Back pain and stiffness, often worse in the morning or after periods of inactivity
- Peripheral joint pain and swelling
- Enthesitis (inflammation at tendon or ligament insertion points)
- Dactylitis (swelling of an entire finger or toe)
- Fatigue
- Uveitis (inflammation of the eye)
- Skin rashes, such as psoriasis
- Inflammatory bowel disease symptoms

Diagnosis typically involves a combination of medical history, physical examination, laboratory tests, and imaging studies. Treatment often includes nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and lifestyle modifications to manage symptoms and prevent joint damage.

Tumor Necrosis Factor (TNF) Receptors are cell surface receptors that bind to tumor necrosis factor cytokines. They play crucial roles in the regulation of a variety of immune cell functions, including inflammation, immunity, and cell survival or death (apoptosis).

There are two major types of TNF receptors: TNFR1 (also known as p55 or CD120a) and TNFR2 (also known as p75 or CD120b). TNFR1 is widely expressed in most tissues, while TNFR2 has a more restricted expression pattern and is mainly found on immune cells.

TNF receptors have an intracellular domain called the death domain, which can trigger signaling pathways leading to apoptosis when activated by TNF ligands. However, they can also activate other signaling pathways that promote cell survival, differentiation, and inflammation. Dysregulation of TNF receptor signaling has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative conditions.

Rheumatic diseases are a group of disorders that cause pain, stiffness, and swelling in the joints, muscles, tendons, ligaments, or bones. They include conditions such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (SLE), gout, ankylosing spondylitis, psoriatic arthritis, and many others. These diseases can also affect other body systems including the skin, eyes, lungs, heart, kidneys, and nervous system. Rheumatic diseases are often chronic and may be progressive, meaning they can worsen over time. They can cause significant pain, disability, and reduced quality of life if not properly diagnosed and managed. The exact causes of rheumatic diseases are not fully understood, but genetics, environmental factors, and immune system dysfunction are believed to play a role in their development.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Tumor Necrosis Factor-alpha (TNF-α) is a cytokine, a type of small signaling protein involved in immune response and inflammation. It is primarily produced by activated macrophages, although other cell types such as T-cells, natural killer cells, and mast cells can also produce it.

TNF-α plays a crucial role in the body's defense against infection and tissue injury by mediating inflammatory responses, activating immune cells, and inducing apoptosis (programmed cell death) in certain types of cells. It does this by binding to its receptors, TNFR1 and TNFR2, which are found on the surface of many cell types.

In addition to its role in the immune response, TNF-α has been implicated in the pathogenesis of several diseases, including autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, as well as cancer, where it can promote tumor growth and metastasis.

Therapeutic agents that target TNF-α, such as infliximab, adalimumab, and etanercept, have been developed to treat these conditions. However, these drugs can also increase the risk of infections and other side effects, so their use must be carefully monitored.

Off-label use refers to the practice of prescribing or using pharmaceutical drugs for purposes, dosages, patient populations, or routes of administration that are not included in the approved labeling of the drug by the regulatory authority, such as the U.S. Food and Drug Administration (FDA). It is not illegal or unethical for physicians to prescribe medications off-label when they judge that it is medically appropriate for their patients. However, manufacturers are prohibited from promoting their drugs for off-label uses.

Catatonic Schizophrenia is a subtype of Schizophrenia characterized by severe psychomotor disturbances such as stupor (reduced reaction to stimuli), mutism (inability to speak), negativism (resistance to instructions or movements), posturing (assuming and maintaining unusual poses), rigidity, agitation, or excitation. These symptoms can lead to significant impairment in daily functioning and quality of life. It is important to note that this subtype is less commonly used in current psychiatric classification systems, as the focus has shifted towards a more comprehensive description of symptom dimensions that cut across traditional diagnostic categories.

Gastrointestinal agents are a class of pharmaceutical drugs that affect the gastrointestinal (GI) tract, which includes the organs involved in digestion such as the mouth, esophagus, stomach, small intestine, large intestine, and anus. These agents can have various effects on the GI tract, including:

1. Increasing gastric motility (promoting bowel movements) - laxatives, prokinetics
2. Decreasing gastric motility (reducing bowel movements) - antidiarrheal agents
3. Neutralizing gastric acid - antacids
4. Reducing gastric acid secretion - H2-blockers, proton pump inhibitors
5. Protecting the mucosal lining of the GI tract - sucralfate, misoprostol
6. Relieving symptoms associated with GI disorders such as bloating, abdominal pain, and nausea - antispasmodics, antiemetics

Examples of gastrointestinal agents include:

* Laxatives (e.g., psyllium, docusate)
* Prokinetics (e.g., metoclopramide)
* Antacids (e.g., calcium carbonate, aluminum hydroxide)
* H2-blockers (e.g., ranitidine, famotidine)
* Proton pump inhibitors (e.g., omeprazole, lansoprazole)
* Sucralfate
* Misoprostol
* Antispasmodics (e.g., hyoscyamine, dicyclomine)
* Antiemetics (e.g., ondansetron, promethazine)

It is important to note that gastrointestinal agents can have both therapeutic and adverse effects, and their use should be based on a careful evaluation of the patient's condition and medical history.

Anti-inflammatory agents are a class of drugs or substances that reduce inflammation in the body. They work by inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes, which are released during an immune response and contribute to symptoms like pain, swelling, redness, and warmth.

There are two main types of anti-inflammatory agents: steroidal and nonsteroidal. Steroidal anti-inflammatory drugs (SAIDs) include corticosteroids, which mimic the effects of hormones produced by the adrenal gland. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a larger group that includes both prescription and over-the-counter medications, such as aspirin, ibuprofen, naproxen, and celecoxib.

While both types of anti-inflammatory agents can be effective in reducing inflammation and relieving symptoms, they differ in their mechanisms of action, side effects, and potential risks. Long-term use of NSAIDs, for example, can increase the risk of gastrointestinal bleeding, kidney damage, and cardiovascular events. Corticosteroids can have significant side effects as well, particularly with long-term use, including weight gain, mood changes, and increased susceptibility to infections.

It's important to use anti-inflammatory agents only as directed by a healthcare provider, and to be aware of potential risks and interactions with other medications or health conditions.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Inflammatory Bowel Diseases (IBD) are a group of chronic inflammatory conditions primarily affecting the gastrointestinal tract. The two main types of IBD are Crohn's disease and ulcerative colitis.

Crohn's disease can cause inflammation in any part of the digestive system, from the mouth to the anus, but it most commonly affects the lower part of the small intestine (the ileum) and/or the colon. The inflammation caused by Crohn's disease often spreads deep into the layers of affected bowel tissue.

Ulcerative colitis, on the other hand, is limited to the colon, specifically the innermost lining of the colon. It causes long-lasting inflammation and sores (ulcers) in the lining of the large intestine (colon) and rectum.

Symptoms can vary depending on the severity and location of inflammation but often include abdominal pain, diarrhea, fatigue, weight loss, and reduced appetite. IBD is not the same as irritable bowel syndrome (IBS), which is a functional gastrointestinal disorder.

The exact cause of IBD remains unknown, but it's thought to be a combination of genetic factors, an abnormal immune response, and environmental triggers. There is no cure for IBD, but treatments can help manage symptoms and reduce inflammation, potentially leading to long-term remission.

Crohn's disease is a type of inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized by chronic inflammation of the digestive tract, which can lead to symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition.

The specific causes of Crohn's disease are not fully understood, but it is believed to be related to a combination of genetic, environmental, and immune system factors. The disease can affect people of any age, but it is most commonly diagnosed in young adults between the ages of 15 and 35.

There is no cure for Crohn's disease, but treatments such as medications, lifestyle changes, and surgery can help manage symptoms and prevent complications. Treatment options depend on the severity and location of the disease, as well as the individual patient's needs and preferences.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

Immunotherapy is a type of medical treatment that uses the body's own immune system to fight against diseases, such as cancer. It involves the use of substances (like vaccines, medications, or immune cells) that stimulate or suppress the immune system to help it recognize and destroy harmful disease-causing cells or agents, like tumor cells.

Immunotherapy can work in several ways:

1. Activating the immune system: Certain immunotherapies boost the body's natural immune responses, helping them recognize and attack cancer cells more effectively.
2. Suppressing immune system inhibitors: Some immunotherapies target and block proteins or molecules that can suppress the immune response, allowing the immune system to work more efficiently against diseases.
3. Replacing or enhancing specific immune cells: Immunotherapy can also involve administering immune cells (like T-cells) that have been genetically engineered or modified to recognize and destroy cancer cells.

Immunotherapies have shown promising results in treating various types of cancer, autoimmune diseases, and allergies. However, they can also cause side effects, as an overactive immune system may attack healthy tissues and organs. Therefore, careful monitoring is necessary during immunotherapy treatment.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

Immunoconjugates are biomolecules created by the conjugation (coupling) of an antibody or antibody fragment with a cytotoxic agent, such as a drug, radionuclide, or toxin. This coupling is designed to direct the cytotoxic agent specifically to target cells, usually cancer cells, against which the antibody is directed, thereby increasing the effectiveness and reducing the side effects of the therapy.

The antibody part of the immunoconjugate recognizes and binds to specific antigens (proteins or other molecules) on the surface of the target cells, while the cytotoxic agent part enters the cell and disrupts its function, leading to cell death. The linker between the two parts is designed to be stable in circulation but can release the cytotoxic agent once inside the target cell.

Immunoconjugates are a promising area of research in targeted cancer therapy, as they offer the potential for more precise and less toxic treatments compared to traditional chemotherapy. However, their development and use also pose challenges, such as ensuring that the immunoconjugate binds specifically to the target cells and not to normal cells, optimizing the dose and schedule of treatment, and minimizing the risk of resistance to the therapy.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Juvenile arthritis (JA) is a term used to describe a group of autoimmune and inflammatory disorders that can affect children aged 16 or younger. In JA, the immune system mistakenly attacks the body's own tissues, causing inflammation in the joints, which can lead to pain, swelling, stiffness, and damage over time.

There are several types of juvenile arthritis, including:

1. Juvenile Idiopathic Arthritis (JIA): This is the most common form of JA, and it includes several subtypes that are classified based on the number of joints affected and the presence or absence of certain symptoms.
2. Juvenile Systemic Lupus Erythematosus (JSLE): This is a type of lupus that affects children, and it can cause inflammation in various parts of the body, including the joints, skin, kidneys, and lungs.
3. Juvenile Dermatomyositis (JDM): This is a rare autoimmune disorder that causes inflammation of the blood vessels, leading to muscle weakness, skin rashes, and joint pain.
4. Juvenile Scleroderma: This is a group of disorders that cause hardening and tightening of the skin and connective tissues, which can also affect the joints.
5. Juvenile Psoriatic Arthritis (JPsA): This is a type of arthritis that affects children who have psoriasis, a chronic skin condition. JPsA can cause inflammation in the joints and skin.

The causes of juvenile arthritis are not fully understood, but it is believed to involve a combination of genetic and environmental factors. There is no cure for JA, but treatments such as medication, physical therapy, and lifestyle changes can help manage the symptoms and prevent long-term complications.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

Ankylosing spondylitis is a type of inflammatory arthritis that primarily affects the spine, although other joints can also be involved. It causes swelling in the spinal joints (vertebrae) that can lead to stiffness and pain. Over time, some of these joints may grow together, causing new bone formation and resulting in a rigid spine. This fusion of the spine is called ankylosis.

The condition typically begins in the sacroiliac joints, where the spine connects to the pelvis. From there, it can spread up the spine and potentially involve other areas of the body such as the eyes, heart, lungs, and gastrointestinal system.

Ankylosing spondylitis has a strong genetic link, with most people carrying the HLA-B27 gene. However, not everyone with this gene will develop the condition. It primarily affects males more often than females and tends to start in early adulthood.

Treatment usually involves a combination of medication, physical therapy, and exercise to help manage pain, maintain mobility, and prevent deformity. In severe cases, surgery may be considered.

Methotrexate is a medication used in the treatment of certain types of cancer and autoimmune diseases. It is an antimetabolite that inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of purines and pyrimidines, essential components of DNA and RNA. By blocking this enzyme, methotrexate interferes with cell division and growth, making it effective in treating rapidly dividing cells such as cancer cells.

In addition to its use in cancer treatment, methotrexate is also used to manage autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In these conditions, methotrexate modulates the immune system and reduces inflammation.

It's important to note that methotrexate can have significant side effects and should be used under the close supervision of a healthcare provider. Regular monitoring of blood counts, liver function, and kidney function is necessary during treatment with methotrexate.

Interleukin-1 Receptor Antagonist Protein (IL-1Ra) is a naturally occurring protein that acts as a competitive inhibitor of the interleukin-1 (IL-1) receptor. IL-1 is a pro-inflammatory cytokine involved in various physiological processes, including the immune response and inflammation. The binding of IL-1 to its receptor triggers a signaling cascade that leads to the activation of inflammatory genes and cellular responses.

IL-1Ra shares structural similarities with IL-1 but does not initiate the downstream signaling pathway. Instead, it binds to the same receptor site as IL-1, preventing IL-1 from interacting with its receptor and thus inhibiting the inflammatory response.

Increased levels of IL-1Ra have been found in various inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease, and sepsis, where it acts to counterbalance the pro-inflammatory effects of IL-1. Recombinant IL-1Ra (Anakinra) is used clinically as a therapeutic agent for the treatment of rheumatoid arthritis and other inflammatory diseases.

... is a monthly peer-reviewed medical journal covering research on all aspects of biological ... "Expert Opinion on Biological Therapy". 2017 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2018. ... therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and ... cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke ...
TNF inhibiting biological therapies were initially used in IBD patients who weren't responding to conventional therapy. They ... which often does not include traditional biological substances like vaccines. Today, biological therapy most commonly refers to ... Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that ... The advancements in biological therapy greatly changed how IBD is treated. Patients with Crohn's disease and ulcerative colitis ...
Expert Opinion on Biological Therapy. 13 (9): 1273-85. doi:10.1517/14712598.2013.819337. PMID 23859704. S2CID 24825173. Li H, ... Epigenetic therapies are reversible, unlike gene therapy. This means that they are druggable for targeted therapies. Diabetes ... However, none of these drugs are likely to be able to replace exposure therapy or other cognitive behavioral therapy methods. ... have been identified as crucial in the exposure therapy process. Successful exposure therapy is associated with increased ...
Expert Opinion on Biological Therapy. 16 (8): 1035-1047. doi:10.1080/14712598.2016.1185412. PMC 4940885. PMID 27145158. Seidl, ... Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It ... It has been said that "α-emitters are indispensable with regard to optimisation of strategies for tumour therapy". The primary ... Kim, Young-Seung; Brechbiel, Martin W. (6 December 2011). "An overview of targeted alpha therapy". Tumor Biology. 33 (3): 573- ...
Zhong R, Platt JL (November 2005). "Current status of animal-to-human transplantation". Expert Opinion on Biological Therapy. 5 ... Cell therapy (also called cellular therapy, cell transplantation, or cytotherapy) is a therapy in which viable cells are ... such as CAR T-cell therapies and allogeneic therapies. Cell and gene therapies require manufacturer and distributors alike to ... Cell therapy can be defined as therapy in which cellular material is injected or otherwise transplanted into a patient. The ...
Expert Opinion on Biological Therapy. 11 (3): 343-357. doi:10.1517/14712598.2011.552884. PMID 21261567. S2CID 19375883. van ... Expert Opinion on Biological Therapy. 14 (10): 1465-76. doi:10.1517/14712598.2014.935332. PMID 24981190. S2CID 26323381. Hanan ... Monoclonal antibody therapy can aid the immune system because the innate immune system responds to the environmental factors it ... Checkpoint therapy uses antibodies and other techniques to circumvent the defenses that tumors use to suppress the immune ...
"Xolair - Biological Therapy". Leung DY, Sampson HA, Yunginger JW, et al. (2003). "Effect of ... Chang is a cofounder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic ... Chang TW, 2000, "The pharmacological basis of anti-IgE therapy." Nature Biotechnology, 18(2), 157-162. Chang TW and Shiung YY, ... anti-IgE therapy in patients with peanut allergy". N. Engl. J. Med. 348 (11): 986-93. doi:10.1056/NEJMoa022613. PMID 12637608. ...
Stigbrand, Torgny; Carlsson, Jorgen; Adams, Gregory P. (2008). Targeted Radionuclide Tumor Therapy: Biological Aspects. ... Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets ... The first therapies in Australia using 177Lu-DOTATATE PRRT for NET began in February 2005 on a trial basis under the ... The first therapies in Turkey using 177Lu-DOTATATE PRRT were carried out in early 2014, for treatment of gastroenteropancreatic ...
"Types of Biological Therapy". SEER Training Modules. National Cancer Institute. Retrieved 14 October 2023. "What are Cancer ... In cell-mediated therapies like CAR-T cell therapy, immune cells are extracted from the patient, genetically engineered to ... T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack ... Adoptive T cell therapy is a form of passive immunization by the transfusion of T-cells (adoptive cell transfer). They are ...
Taylor RW (February 2005). "Gene therapy for the treatment of mitochondrial DNA disorders". Expert Opinion on Biological ... Presently, gene therapy and nutraceutical supplementation are popular areas of ongoing research. Bjelakovic et al. analyzed the ... An IVF technique known as mitochondrial donation or mitochondrial replacement therapy (MRT) results in offspring containing ... The Journal of Biological Chemistry. 281 (1): 374-382. doi:10.1074/jbc.M509730200. PMID 16263719. Jemt E, Farge G, Bäckström S ...
Expert Opinion on Biological Therapy. 15 (8): 1155-72. doi:10.1517/14712598.2015.1051527. PMC 4883659. PMID 26027436. Loh QL, ... Series B, Biological Sciences. 362 (1484): 1505-12. doi:10.1098/rstb.2007.2131. PMC 2440411. PMID 17588875. Gandaglia A, Bagno ... Studies led by Dohmen, Konertz, and colleagues in Berlin, Germany involved the implantation of a biological pig valve in 50 ... While current treatments offered such as mechanical valves or biological valves are not deleterious to one's health, they both ...
Goldstein, A.L. and Garaci, E., Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious ... Expert Opinion on Biological Therapy. 18 (sup1): 77-83. doi:10.1080/14712598.2018.1494717. ISSN 1744-7682. OCLC 768086347. PMID ... Expert Opinion on Biological Therapy. 18 (sup1): 9-11. doi:10.1080/14712598.2018.1484447. ISSN 1471-2598. OCLC 644930062. PMID ... Goldstein's research has helped define the role of biological response modifiers in health and disease, and has led to the ...
Other treatment options include biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of ... "National Comprehensive Cancer Network" (PDF). "Biological therapy for kidney cancer". 2017-08-30. Jonasch, Eric; Messner, ... Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Kidney cancer newly ... Sex The incidence of kidney cancer is two times greater in men than in women, and this is thought to be due to biological ...
Expert Opinion on Biological Therapy. 9 (5): 649-657. doi:10.1517/14712590902926071. PMID 19392579. S2CID 70711735. Schubert- ...
Triozzi, PL; Borden, EC (December 2011). "VB-111 for cancer". Expert Opinion on Biological Therapy. 11 (12): 1669-76. doi: ... Ofranergene obadenovec, also known as VB-111, is an anti-angiogenic gene therapy. The vector is a non-replicating adenovirus 5 ...
Expert Opinion on Biological Therapy. 9 (12): 1521-1531. doi:10.1517/14712590903307388. PMID 19780714. S2CID 21927486. ... Gene therapy vectors (such as viruses) can be PEG-coated to shield them from inactivation by the immune system and to de-target ... An example of PEG hydrogels (see Biological uses section) in a therapeutic has been theorized by Ma et al. They propose using ... PEGylation of adenoviruses for gene therapy can help prevent adverse reactions due to pre-existing adenovirus immunity. A ...
Expert Opinion on Biological Therapy. 7 (5): 713-26. doi:10.1517/14712598.7.5.713. PMID 17477808. S2CID 12725001. "The rise and ... The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that ... Series B, Biological Sciences. 356 (1406): 185-95. doi:10.1098/rstb.2000.0764. PMC 1088424. PMID 11260799. Geschwind, MD (2015 ... "Use of Pentosan Polysulphate in the treatment of, or prevention of, vCJD". Department of Health:CJD Therapy Advisory Group. ...
Trobridge GD (November 2009). "Foamy virus vectors for gene transfer". Expert Opinion on Biological Therapy. 9 (11): 1427-1436 ... it may be a better vector for gene therapy than other foamy viruses. The budding characteristic of EFV from the plasma membrane ...
McLaughlin EA, Holland MK, Aitken RJ (August 2003). "Contraceptive vaccines". Expert Opinion on Biological Therapy. 3 (5): 829- ... At the same time, he got a phone call from the University of Newcastle, inviting him to take up the Chair of Biological ... He was born in Bath, England but moved to Australia in 1997, where he took Chair of Biological Sciences at the University of ... Newcastle, then nominated to Pro-Vice-Chancellor of the Faculty of Health and Medicine and Laureate Professor of Biological ...
Expert Opinion on Biological Therapy. 10 (2): 163-78. doi:10.1517/14712590903431022. PMC 2809805. PMID 19947897. "Anti-GD2 for ... It is given in patients who have completed induction therapy and consolidation therapy (autologous bone marrow transplant and ... external beam radiation therapy), as part of standard-of-care therapy for newly-diagnosed high-risk neuroblastoma. It is given ... Dinutuximab is used as post-consolidation therapy for children with high-risk neuroblastoma, in combination with granulocyte- ...
Expert Opinion on Biological Therapy. 21 (7): 931-943. doi:10.1080/14712598.2020.1776255. PMID 32543981. S2CID 219725417. " ... The drug is also being evaluated broadly across multiple lines of therapy in patients with myeloid malignancies, including in ... Hartley JA (July 2021). "Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy". ...
Expert Opinion on Biological Therapy. 20 (8): 831-836. doi:10.1080/14712598.2020.1767062. PMID 32380868. S2CID 218556295. ... a potential therapy agent for lung cancer". Cancer Gene Therapy. 17 (4): 256-65. doi:10.1038/cgt.2009.74. PMID 19893593. S2CID ... Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X (July 2003). "Effective therapy of metastatic ovarian cancer with an ... Ilyinskaya GV, Mukhina EV, Soboleva AV, Matveeva OV, Chumakov PM (2018). "Oncolytic Sendai Virus Therapy of Canine Mast Cell ...
Expert Opinion on Biological Therapy. Informa UK Limited. 20 (9): 1061-1072. doi:10.1080/14712598.2020.1749259. PMID 32228250. ... "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021. "Drug ... Clinical trial number NCT02028884 for "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat ...
Expert Opinion on Biological Therapy. 8 (12): 1955-1962. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842. Kupchik ... Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other therapies in respiratory ... Wong KK, Lee SW, Kua KP (2021). "N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the ... Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-Acetylcysteine for antioxidant therapy: pharmacology and ...
Expert Opinion on Biological Therapy. 7 (5): 599-615. doi:10.1517/14712598.7.5.599. PMID 17477799. S2CID 43003664. Watzl C ( ... Toxic effects of CAR T therapy, such as CSR, have not been observed with the use of CAR NK cells. Thus, NK cells are considered ... However, wider use is limited by several fundamental problems: The high cost of CAR T cell therapy, which is due to the need to ... VTX-2337 is a selective TLR-8 agonist and together with monoclonal antibody cetuximab it was used as a potential therapy for ...
Expert Opinion on Biological Therapy. 14 (8): 1175-1184. doi:10.1517/14712598.2014.912272. PMID 24766232. S2CID 24820913. " ... "What is gene therapy?". NIH: U.S. National Library of Medicine. Ledford H (2011). "Cell therapy fights leukaemia". Nature. doi: ... Most commonly used in human cells are germline gene therapy and the engineered nuclease system CRISPR/Cas9. Gene therapy is the ... Stein CA, Castanotto D (May 2017). "FDA-Approved Oligonucleotide Therapies in 2017". Molecular Therapy. 25 (5): 1069-1075. doi: ...
Hall, R. A.; Khromykh, A. A. (2004). "West Nile virus vaccines". Expert Opinion on Biological Therapy. 4 (8): 1295-1305. doi: ... Titball, R. W.; Williamson, E. D. (2004). "Yersinia pestis (plague) vaccines". Expert Opinion on Biological Therapy. 4 (6): 965 ... Expert Opinion on Biological Therapy. 10 (2): 179-190. doi:10.1517/14712590903379502. PMID 20088713. S2CID 2700243. Schleiss, M ... A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent ...
Expert Opinion on Biological Therapy. 10 (1): 127-31. doi:10.1517/14712590903490382. PMID 20420518. S2CID 13626456. Muzii L, ... Experience in the use of anti-sclerotic therapy (longidase 3000 IU, rectal suppositories) in the complex treatment of chronic ... The effectiveness of the use of Longidase in the complex therapy of patients with pulmonary tuberculosis]. Здоровье и ... molecular weight copolymer that forms a component of combination therapy regimens for treatment and prevention of diseases ...
Pascolo S (August 2004). "Messenger RNA-based vaccines". Expert Opinion on Biological Therapy. 4 (8): 1285-94. doi:10.1517/ ... Another biological advantage of mRNA vaccines is that since the antigens are produced inside the cell, they stimulate cellular ... It is useful in gene therapy, vaccination, and any therapeutic situation in which a polypeptide should be administered to cells ... Bloom K, van den Berg F, Arbuthnot P (April 2021). "Self-amplifying RNA vaccines for infectious diseases". Gene Therapy. 28 (3- ...
Expert Opinion on Biological Therapy. 18 (4): 425-448. doi:10.1080/14712598.2018.1438406. PMID 29431518. Zhao ZT, Ji CM, Yu WJ ... Perhaps the most dramatic effect, which was not foreseen at the time when the anti-IgE therapy was designed and which was ... In conjunction with achieving the practical goal to investigate the applicability of the anti-IgE therapy as a potential ... This seems to be contrary to the general understanding of the pharmacological mechanisms of the anti-IgE therapy discussed ...
Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological ... "Expert Opinion on Biological Therapy". 2017 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2018. ... therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and ... cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke ...
During the past decade, different strategies to initiate pacemaker function by gene therapy were d … ... Gene therapy to create biological pacemakers Med Biol Eng Comput. 2007 Feb;45(2):167-76. doi: 10.1007/s11517-006-0112-7. Epub ... During the past decade, different strategies to initiate pacemaker function by gene therapy were developed. In the search for a ... biological pacemaker, various approaches were explored, including beta(2)-adrenergic receptor overexpression, down regulation ...
Innovative/Biological Therapies in Sports Injury. On 28th March 2017, the Biosport project team, in conjunction with Professor ... medical insurers and trade union reps to discuss and debate the use of innovative and biological therapies in treating sports ...
... have played an increasingly important role in the characterization and evaluation of biosafety for human biological therapies. ...
BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as the woman who wants to genetically ... Curing biological Aging & Gene Therapy with Liz Parrish and Dr. Nick Delgado at RaadFest, Las Vegas Posted by Paul Battista in ... BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as "the woman who wants to genetically ...
... ... "If this turns out to really work, it will be a game-changer for part of the therapy for COVID-19 lung disease," LSU health ...
HyTEC 2103 - Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): ... High-dose stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS) kill tumor cells not only through ...
Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with ... Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with ... Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with ...
Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: ... Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: ...
Psoriasis treated with biological therapies does not raise the risk of infection in people undergoing immune-modulating ... It found none of the biological therapies studied had a higher risk of infection compared to non-biological therapies or ... No biological therapy had a higher risk of infection than another biological therapy, after accounting for confounding factors. ... compared to non-biological oral therapies (hazard ratio for all biological therapies combined 0.96, 95% confidence interval [CI ...
After prior anti-TNF therapy failure, vedolizumab and tofacitinib in UC patients and vedolizumab and ustekinumab in CD patients ... However, direct comparisons of the effectiveness of second-line biological agents in patients with ulcerative colitis (UC) and ... weeks after receiving induction therapy. A total of 94 patients with UC or CD experienced anti-TNF treatment failure and ... Hyun, H.K., Zhang, HS., Yu, J. et al. Comparative effectiveness of second-line biological therapies for ulcerative colitis and ...
Cancer Biological Therapy Market size was estimated at $112 Bn in 2022 and is projected to hit $220 Bn, Set to record a CAGR of ... What is cancer biological therapy? Biological therapy or biotherapy is a new cancer treatment method. It makes use of ... Cancer Biological Therapy Market: Overview. Biological therapy or biotherapy is a new cancer treatment method. It makes use of ... Cancer Biological Therapy Industry Perspective: The global cancer biological therapy market size was evaluated at $112 billion ...
This is called biological therapy, or immunotherapy.. The most common form of biological therapy is Bacillus Calmette-Guerin ... Biological therapy. Treatment for early stage bladder cancer might involve encouraging the immune system to fight cancer cells ... Interferon is another biological therapy option. The immune system makes this protein to fight infection, and a synthetic ... Radiation therapy. Radiation therapy is a less common intervention for bladder cancer. Doctors may recommend it in combination ...
Copyright 2021 Empowered Therapy & Training All Rights Reserved , ABN: 55 637 079 620 ... Junior Biological Sciences. Digital download as PDF. ...
Chan, S., & Watson, A. J. M. (2013). Bacterial translocation influences the response to biological therapy in Crohns disease. ... Bacterial translocation influences the response to biological therapy in Crohns disease. / Chan, Simon; Watson, Alastair J M. ... Chan, Simon ; Watson, Alastair J M. / Bacterial translocation influences the response to biological therapy in Crohns disease ... Bacterial translocation influences the response to biological therapy in Crohns disease. Simon Chan, Alastair J M Watson ...
Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive inflammatory ...
Biological therapy. Works with your bodys immune system to help it fight cancer cells or to control side effects from other ... Radiation therapy. Using high-energy rays (similar to X-rays) to kill the cancer cells. ... Hormonal therapy. Blocks cancer cells from getting the hormones they need to grow. ...
BMC Complementary Medicine and Therapies ISSN: 2662-7671. Contact us. *Submission enquiries: ... From: Acthaside: a new chromone derivative from Acacia ataxacantha and its biological activities ...
BRAF inhibitors on Immune-based antitumor therapy. Tag: LCL-161 biological activity. This review highlights the progress made ... food intake and core body temperature with male guinea pigs exhibiting a comparatively greater LCL-161 biological activity ... Categorized as MDR Tagged LCL-161 biological activity, Rabbit polyclonal to ANKDD1A ...
This type of therapy uses viruses that have been altered in a lab to infect and kill cancer cells. When these cells die, they ... These therapies boost the immune system in more general way than monoclonal antibodies. There are two main types: Interleukin-2 ... These therapies can also cause a severe, sometimes fatal, allergic reaction in people sensitive to certain ingredients in the ... Called monoclonal antibodies, they are also a type of targeted therapy. Some monoclonal antibodies work by sticking to cancer ...
Immunotherapy or Biological Therapy. Biological therapy takes advantage of the bodys natural ability to fight cancer. ... Standard therapies for bladder cancer include surgery, radiation therapy, chemotherapy, and immunotherapy or biological therapy ... Different Therapies *What Are the Roles of Chemotherapy, Immunotherapy, and Biological Therapy in the Treatment of Bladder ... Biological therapy is typically given only in stages Ta, T1, and CIS bladder cancers. ...
How traditional therapy and Biological Decoding complement each other. Biological Decoding isnt a substitute for any medical ... Biological Decoding is effective as a supportive therapy, it helps a person to locate the conflict events that are the origin ... With this information, Biological Decoding therapy can support the person, helping them to release the stress associated to an ... Biological Decoding is a complementary supportive therapy. If the practitioner is given information about the treatment that ...
Biological and targeted therapy for the treatment of psoriasis and psoriatic arthritis. отGP News публикувано на 28.08.2023. ... Rheumatology and Diseases of the Joints / Biological and targeted therapy for the treatment of psoriasis and psoriatic ...
Biological therapy. The following medications are used in the management of hidradenitis suppurativa:. * Antibiotics (eg, ... Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol. 1999 Dec. 141(6):1138-9. [QxMD MEDLINE Link]. ... Nonablative radiofrequency therapy can be used for patients with Harley stage I and II disease. [17] ... Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?. Br J ...
... a system capable of providing neuromodulation therapy and biological sensing in support of next generation therapies was ... Research and Opinion: Neuromodulation Therapy and Biological Sensing System Posted on March 30, 2022. Updated January 24, 2023 ... From the article: Neuromodulation systems currently provide therapy for many diseases. Advancing therapy capabilities is an ...
Method to analyze effects of low-level laser therapy on biological cells with a digital holographic microscope.. Baczewska, ... Low-level laser therapy (LLLT) is a therapeutic tool that uses the photobiochemical interaction between light and tissue. Its ... The proposed methodology has been designed to provide a basis for many other biological experiments using quantitative phase ... that digital holographic microscopy is an effective label-free imaging technique to analyze the effects of LLLT on biological ...
The goals of therapy and the measures required to achieve them depend on the stage of the disease and are therefore sensibly ... T therapy for enlarged prostate. Order cialis online discount - Online Canadian Pharmacy #1 In The World. Tartalom ... Pulmonary hypertension - state of the art of modern therapies. Our products R Radiation protection The Chernobyl nuclear ... Consultation version S3 guideline Diagnostics, therapy and follow-up of renal cell carcinoma. Long version 3. ...
There has been considerable interest in biological therapies for emerging epidemic threats (29). Convalescent-phase plasma and ... History of Biological Standardization. The concept of biological standardization and the use of biological reference materials ... International Biological Reference Preparations for Epidemic Infectious Diseases On This Page History of Biological ... The international contribution to the standardization of biological substances. I. Biological standards and the League of ...
Biological & Advanced Therapies. • Clinical Drug Development. • Drug Development Statistics & Data Management. • Drug ...
  • The results should encourage adherence to the recent British Association of Dermatology guideline on the use of biologic therapies in psoriasis. (
  • While biologic and small molecule therapies are effective IBD treatments, some therapies have been implicated in an increased risk for MACE. (
  • A biopharmaceutical (biological or biologic), which consists of sugars, proteins, nucleic acids, living cells, or tissues, is a medicinal product manufactured in extracted or semi-synthesized from biological sources like humans, animals, or microorganisms. (
  • Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and cell- and tissue-based therapies. (
  • The Expert Committee on Biological Standardization meets annually to establish detailed recommendations and guidelines for manufacturing, licensing, and control of complex biological materials, including blood products, vaccines, and related in vitro diagnostic tests, and to maintain a catalog of IRPs to be distributed globally as required. (
  • This session was recorded as part of FDLI's Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies Course in October 2023. (
  • approaches to develop new medicines, biological therapies and vaccines, which can be brought to the forefront of this fight faster than ever before. (
  • On 28th March 2017, the Biosport project team, in conjunction with Professor Ilyas Khan (Swansea University) are bringing together leading scholars, clinicians and practioners in sports medicine along with biotechnology company representatives, medical insurers and trade union reps to discuss and debate the use of innovative and biological therapies in treating sports injuries. (
  • NICE 2017 guidance recommends use of certain biological therapies, including etanercept, adalimumab and ustekinumab, for moderate to severe psoriasis, when standard oral therapy has not worked or cannot be used. (
  • British Association of Dermatologists 2017 guidance recommends adalimumab, ustekinumab and secukinumab as first-line biological therapies, with etanercept as a second-line choice, because clinical trials have shown it to be less effective. (
  • Cancer is one of the key causes of death across the globe and in the last few years, a large number of research studies have demonstrated the necessity of introducing new treatments for reducing the side effects due to traditional therapies. (
  • High-dose stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS) kill tumor cells not only through directly damaging DNA but also by causing vascular damage and increasing tumor hypoxia, thereby inducing indirect/secondary tumor cell death. (
  • S16.00001: The Evolution of External Beam Radiation Therapy (EBRT) from a Technological Perspective. (
  • Biology-guided radiotherapy (BgRT) uses real-time functional imaging to guide radiation therapy treatment. (
  • Biology-guided radiotherapy (BgRT) is a novel therapeutic modality that intends to guide radiation therapy using functional imaging such as positron emission tomography (PET) ( 1 - 3 ). (
  • The PET-linac may be used to deliver intensity-modulated radiotherapy (IMRT), stereotactic surgery (SRS), and stereotactic ablative radiation therapy (SABR). (
  • The global cancer biological therapy market size was evaluated at $112 billion in 2022 and is slated to hit $220 billion by the end of 2030 with a CAGR of nearly 7.2% between 2023 and 2030. (
  • The global cancer biological therapy market is anticipated to record massive growth over the forecast period owing to the cancer biological therapies like oncolytic virus therapy and immunotherapy are well tolerated by the bodies of the patients and have low side-effects as compared to chemotherapies due to its effective immune tolerance mechanisms . (
  • Moreover, cancer biological therapies like oncolytic virus therapy and immunotherapy are well tolerated by the bodies of the patients and have low side effects as compared to chemotherapies due to their effective immune tolerance mechanisms. (
  • This is called biological therapy, or immunotherapy. (
  • Hormone therapy is a treatment option for advanced prostate cancer, as are chemotherapy and immunotherapy . (
  • The primary outcomes were the clinical remission rate at week 16 and the cumulative relapse rate 48 weeks after receiving induction therapy. (
  • After prior anti-TNF therapy failure, vedolizumab and tofacitinib in UC patients and vedolizumab and ustekinumab in CD patients were not significantly different in terms of the efficacy in inducing and maintaining a clinical response. (
  • However, recently, "treat-to-target therapy" has been used to reduce complications and improve patients' quality of life based not only on clinical symptoms but also on the normalisation of bowel structure and function through mucosal healing [ 2 ]. (
  • Use of IRPs also ensures consistency of production and quality of biological medicinal products and is essential for establishment of appropriate clinical dosing. (
  • Since 1947, the provision of WHO reference materials has played a vital role in the translation of laboratory science into worldwide clinical practice and has been delivered through the WHO Expert Committee on Biological Standardization, WHO collaborating centers, and various state and nonstate partners. (
  • She had received one cycle of Rituximab with clinical and biological failure. (
  • She received the first cycle of Rituximab made of two intravenous infusions at 2-week intervals (1 g/infusion) but five months later, she presented another severe RA flare (DAS28 = 6.2) concluding to the clinical and biological failure of Rituximab. (
  • The DANBIO registry has collected data prospectively on clinical efficacy from all rheumatological patients in Denmark treated with biological agents since 2000, which makes it suitable for studying the use of biological agents in clinical practice. (
  • However, because no data exist regarding the efficacy of this therapy for persons with nonoccupational HIV exposure, it should be considered an unproven clinical intervention. (
  • Objective: To update the recommendations for the treatment of axial spondyloarthritis (axSpA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. (
  • The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. (
  • Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? (
  • The treatment of rheumatoid arthritis (RA) has improved substantially after the introduction of tumour necrosis factor alpha (TNFα) inhibitors and other biological agents. (
  • People with psoriasis who take an immune-modulating treatment are no more likely to get serious infections than people taking standard therapies. (
  • Researchers used data from a large, national registry of people with psoriasis - the British Association of Dermatologists Biological Interventions Register - to carry out a prospective cohort study. (
  • Immunoassays such as ELISAs or molecular methods such as quantitative PCR can be used to quantify biological materials, but these assays are subject to inherent variability between test instances and different laboratories, and require the use of reference preparations to generate a quantitative output ( 2 ). (
  • Milder local disease can be managed with creams, but people often need oral treatment, initially non-biological but often biological therapies, which are prescribed and monitored by specialists. (
  • Infliximab was the first biological product approved by the Food and Drug Administration in 1998 and the European Medicines Agency in 1999 for the treatment of moderate to severe IBD, and other biosimilar agents are now available [ 4 ]. (
  • Biological therapy or biotherapy is a new cancer treatment method. (
  • These therapies can also cause a severe, sometimes fatal, allergic reaction in people sensitive to certain ingredients in the treatment. (
  • I'll explain how Biological Decoding is complementary to any kind of treatment. (
  • The word therapy (from the Greek "therapeia") means treatment. (
  • Many biological, treatment specific and social factors are affecting treatment resistance. (
  • 1813 patients with RA starting treatment with biological agents in 2000-5 were registered prospectively in the nationwide DANBIO Registry. (
  • The aim of this study was to evaluate the trend in treatment response and drug survival in cohorts of patients with RA treated with a biological drug from 2000 to 2005. (
  • Despite the tremendous possibilities for the treatment of many diseases, progress in nucleic acid therapy is very slow. (
  • The first recommendation is a general statement indicating that biological therapy is not a first-line drug treatment option and should only be used after conventional treatment has failed. (
  • System design strategies, biological therapies, and church-based mental health promotion initiatives are all considered as methods for reducing racial and ethnic disparities in access to effective treatment. (
  • During BgRT treatment, detection of annihilation photons originating from a volume called the biological tracking zone (BTZ) triggers the delivery of beamlets of radiation to the lesion with sub-second latency. (
  • Treatment protocols for colon cancer are provided below, including adjuvant and neoadjuvant therapy for resectable disease and therapy for advanced or metastatic colon cancer. (
  • These preparations are the basis of a uniform reporting system, helping physicians and scientists involved in patient care, regulatory authorities and manufacturing settings to communicate in a common language for designating the activity or potency of biological preparations used in prophylaxis or therapy, and ensuring the reliability of in vitro biological diagnostic procedures used for diagnosis of diseases and treatment monitoring. (
  • ABSTRACT We assessed the effectiveness of photodynamic therapy in the treatment of cutaneous leishmaniasis in 5 patients. (
  • No patients taking adalimumab or ustekinumab died within 30 days of the infection, compared to fewer than five taking etanercept and seven taking non-biological therapies. (
  • However, direct comparisons of the effectiveness of second-line biological agents in patients with ulcerative colitis (UC) and Crohn's disease (CD) are lacking. (
  • To achieve these therapeutic goals, new biological agents have been introduced, altering the paradigm of therapeutic strategies in IBD patients. (
  • In addition, a secondary loss of response, defined as worsening of symptoms, can occur as a result of active IBD during maintenance therapy in patients with prior disease control after induction therapy. (
  • Randomised controlled trials (RCTs) have demonstrated impressive efficacy in patients with severe disease, and the biological drugs are now widely used. (
  • From 1 October 2000 to 31 December 2005, 1813 patients with RA, who initiated biological therapy for the first time were registered in the nationwide DANBIO Registry. (
  • Our thought was that we would not see an increase in MACE and it would be equivalent between patients with IBD treated with advanced therapies and patients not treated with advanced therapies," he told Medscape Medical News . (
  • 0001) compared with IBD patients not on biological therapy. (
  • Results: A consensus was achieved regarding the initiation, assessment of response and switching of biological therapies in patients with axSpA. (
  • Conclusion: These recommendations may be used for guidance in deciding which patients with axSpA should be treated with biological therapies. (
  • Methods: From January 1993 to July 2014, 694 patients underwent repeat biological valve replacement at our clinic. (
  • The advent of kinase inhibitors such as ibrutinib has demonstrated significantly improved responses as second line therapies as well as improved responses in patients with 17p deletion compared to standard chemoimmunotherapy regimens with long (more than two years) durable remissions in the majority of patients. (
  • however, adjuvant therapy may be considered in patients with high-risk disease. (
  • These WHO IRPs, composed of international reference standards and other reference materials ( Table 1 ), provide a common set of reagents that are used to ensure the quality of biological assays and medicines globally. (
  • The concept of TCIM that we are using is wide and inclusive, and encompasses all traditional medicines/healthcare systems, and other recognized medical systems, as well as health practices and therapies that are generally understood within TCI Medicine. (
  • Low-level laser therapy ( LLLT ) is a therapeutic tool that uses the photobiochemical interaction between light and tissue . (
  • This positive therapeutic response will contribute to increase literature reports of this therapy success. (
  • Such use is contrary to international law and has rarely taken place during formal warfare in modern history, despite the extensive preparations and stockpiling of biological agents carried out during the 20th century by most major powers (including development of strains resistant to multiple drugs). (
  • No biological therapy had a higher risk of infection than another biological therapy, after accounting for confounding factors. (
  • Interferon is another biological therapy option. (
  • Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive inflammatory responses in the asthmatic lung. (
  • Different from traditional drugs synthesized from chemical processes, the majority of biopharmaceutical products are derived from biological processes including the extraction from living systems or the production by recombinant DNA technologies ( Table 1 ). (
  • In the search for a biological pacemaker, various approaches were explored, including beta(2)-adrenergic receptor overexpression, down regulation of the inward rectifier current, and overexpression of the pacemaker current. (
  • Although health-care providers and others have proposed offering antiretroviral drugs to persons with unanticipated sexual or injecting-drug-use HIV exposures (3,4), no data exist regarding the effectiveness of such therapy for these types of exposures. (
  • It is not clear whether serious infections are more common with biological therapies than non-biological immunosuppressant oral treatments, such as methotrexate. (
  • They excluded the biological therapy secukinumab because few people had used it, and infliximab because the prescribing criteria mean it is used by people with more severe disease. (
  • We investigated whether infliximab, an anti-TNF-alpha therapy, may modify the lipid profile. (
  • These therapies boost the immune system in more general way than monoclonal antibodies. (
  • Tumour necrosis factor (TNF), a proinflammatory cytokine, was found to be one of the key cytokines that initiate and perpetuate intestinal inflammation in IBD, and anti-TNF agents have been considered first-line biological agents for treating moderate to severe UC or CD. (
  • Switching Biological Therapies in Severe Asthma. (
  • In the field of gene therapy, special interest goes to nanoparticles containing nucleic acids, such as plasmid DNA and small interference RNA. (
  • Chan, S & Watson, AJM 2013, ' Bacterial translocation influences the response to biological therapy in Crohn's disease ', Gastroenterology , vol. 145, no. 4, pp. 898-901. (
  • During the past decade, different strategies to initiate pacemaker function by gene therapy were developed. (
  • Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. (
  • The management of inflammatory bowel disease has changed dramatically with the development of immunosuppressive and biological therapies. (
  • Called monoclonal antibodies, they are also a type of targeted therapy . (
  • Consultation version S3 guideline Diagnostics, therapy and follow-up of renal cell carcinoma. (
  • Biological exposure indices. (
  • Antiretroviral therapy should never replace adopting and maintaining behaviors that guard against HIV exposure (e.g., sexual abstinence, sex only with an uninfected partner, consistent and correct condom use, abstinence from injecting-drug use, and consistent use of sterile equipment by those unable to cease injecting-drug use). (
  • Virtual reality as a mechanism for exposure therapy. (
  • Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. (
  • It makes use of biological response modifiers as well as biologicals for treating cancer. (
  • Moreover, biological response modifiers or biologicals originate from mammalian cells and improve the immune response. (
  • One of the important causes is the lack of suitable methods to study the physicochemical characteristics of nanomedicines in the relevant biological media. (
  • By using advanced microscopy methods like fluorescence correlation spectroscopy, single particle tracking and fluorescence nanoscopy, this project aims at obtaining a more fundamental insight into the structure and the biophysical properties of nucleic acid nanoparticles in the biological media in which they end up after administration. (
  • Experimental data regarding the physical and biological processes that control bone adaptation reveal new avenues of therapy, which have the potential to augment bone mass and strength significantly. (
  • In July 1997, CDC sponsored the External Consultants Meeting on Antiretroviral Therapy for Potential Nonoccupational Exposures to HIV. (
  • Ibrutinib is the first BTK inhibitor that has reached the clinic and is approved as therapy for relapsed/refractory CLL. (
  • The proposed methodology has been designed to provide a basis for many other biological experiments using quantitative phase imaging. (
  • Learn the statutory definitions of a biological product as well as recognize the distinctions that drive jurisdiction and regulatory pathways. (
  • A biopsy of an enlarged lymph node or bone marrow will be taken and examined to figure out the specific type of cancer based on several tissue biological markers as well as cell structure. (
  • A 45-year-old Moroccan woman, with the history of thyroidectomy for 18 years ago receiving the thyroid hormone replacement therapy. (
  • The launching of molecular biological procedures and hybridoma technology has resulted in the preparation of these substances in huge quantities and highly pure form to apply them in cancer biological therapy. (
  • Advancing therapy capabilities is an important goal in the design of next generation devices, but consideration of user concerns needs to be included in design updates. (
  • Neuromodulation systems currently provide therapy for many diseases. (
  • Our products R Radiation protection The Chernobyl nuclear accident has led to a sharp increase in radiation-induced thyroid cancer in children and adolescents t therapy for enlarged prostate the heavily contaminated areas of Ukraine, Belarus and Russia. (
  • This concept was applied by Dale in the 1920s to other biological products, such as insulin, but the need for international oversight was recognized ( 6 ). (
  • Understand the applicability of both the PHS Act and the FDCA to biological products. (
  • It compared serious infection risk of the biological therapies (etanercept, adalimumab or ustekinumab) with non-biological therapies, after accounting for factors such as other illnesses. (
  • It found none of the biological therapies studied had a higher risk of infection compared to non-biological therapies or compared to each other. (
  • They compared serious infection rates for 3,421 people taking non-biological oral therapies, and 5,617 people taking etanercept, adalimumab or ustekinumab. (
  • None of the biological therapies had a statistically significant increased risk of serious infection, compared to non-biological oral therapies (hazard ratio for all biological therapies combined 0.96, 95% confidence interval [CI] 0.73 to 1.27). (
  • Assistant to the Secretary of Defense for Nuclear and Chemical and Biological Defense Programs, Washington, DC. (
  • PAH is a very rare disease: t therapy for enlarged prostate Europe, approximately new cases of PAH per 1 million population are diagnosed annually. (
  • Biological warfare (BW) is the use of microbiological agents for hostile purposes. (
  • Biological-warfare agents are thought by some to be an ideal weapon for terrorists. (
  • In terms of revenue, the global cancer biological therapy market size was evaluated at nearly $112 billion in 2022 and is expected to reach $220 billion by 2030. (
  • Region-wise, the Europe cancer biological therapy market is projected to register the highest CAGR during the assessment timeline. (
  • This aspect is predicted to drive the global cancer biological therapy market trends. (
  • This type of therapy uses viruses that have been altered in a lab to infect and kill cancer cells. (
  • This report reviews the topics raised at the meeting, provides background information on patient management options, and presents considerations for antiretroviral therapy. (
  • We outline the need for internationally standardized biological materials for high-threat pathogens as a core element of global health security. (
  • WHO provides Biological Reference Materials which serve as reference sources of defined biological activity expressed in an internationally agreed unit. (